#USA #DJS Law Group #Eastchester #Soleno Therapeutics #SLNO

Soleno Therapeutics, Inc. Faces Legal Challenge

Soleno Therapeutics, Inc., known by its ticker symbol SLNO on NASDAQ, has encountered a significant hurdle as it faces a class action lawsuit. This legal action stems from accusations of violating several securities laws, particularly sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission.

Key Details of the Lawsuit

Class Period

The class action involves investors who acquired Soleno shares during the period from March 26, 2025, to November 4, 2025. With a deadline set for May 5, 2026, those affected are encouraged to seek information regarding potential participation in the legal proceedings.

Allegations against Soleno

The crux of the complaint highlights the company's communication to the market, which is alleged to have included false and misleading statements. As per the lawsuit, specific details emerged during Soleno's Phase 3 clinical trial regarding its drug candidate, diazoxide choline extended-release tablets (DCCR). The trial reportedly raised safety concerns, which the company downplayed significantly.

This negligence has affected the perceived viability of DCCR in the market, raising questions about the authenticity of Soleno's public statements throughout the class period. Such misleading information has had a detrimental impact on shareholders who might have experienced losses as a result.

What Should Shareholders Do?

For individuals who are among the investors affected by these alleged securities violations, the DJS Law Group is providing an opportunity for participation in the case. Interested shareholders do not necessarily need to be appointed as lead plaintiffs to qualify for potential recovery of losses incurred during the disputed timeframe.

The emphasis from DJS Law Group is on enhancing investor return through strategic insights and proactive representation in securities class actions. Their track record includes work with some of the largest hedge funds and asset managers worldwide, positioning them as a competent advocate in this realm of litigation.

Importance of Legal Representation

The ramifications of this case are substantial not only for Soleno but also for its investor base. As the legal proceedings unfold, affected shareholders must remain informed about the developments in the lawsuit. Proper legal representation is crucial to navigate the complexities involved in securities litigation.

Contacting the DJS Law Group could be a critical step for those seeking to understand their rights as shareholders and to discuss potential strategies for recovering losses related to this case.

Conclusion

In conclusion, the situation surrounding Soleno Therapeutics encapsulates a pressing challenge within the sector of health and pharmaceuticals, where investor protections and regulatory oversight are vital. Those affected should act swiftly and consult experts to explore their options in this class action lawsuit.

For more detailed inquiries, shareholders can reach out to:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]